Form 4: OnKure Therapeutics Executive Receives Stock Grant
Insider Transaction (Form 4)
Dylan Hartley, Chief Scientific Officer of OnKure Therapeutics, Inc., reported multiple transactions in common stock on August 7, 2026.
Summary
- Grant/award: acquired 50,000 Employee Stock Option (right to buy) on August 7, 2026; holds 50,000 after (Direct).
- Disposition to the issuer: disposed of 137,603 Employee Stock Option (right to buy) on August 7, 2026 (Direct).
- Grant/award: acquired 137,603 Employee Stock Option (right to buy) on August 7, 2026; holds 137,603 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Dylan Hartley — Officer (Chief Scientific Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-07 | Grant/award | Employee Stock Option (right to buy) | 50,000 | — | — | 50,000 |
| 2026-08-07 | Disposition to the issuer | Employee Stock Option (right to buy) | 137,603 | — | — | 0 |
| 2026-08-07 | Grant/award | Employee Stock Option (right to buy) | 137,603 | — | — | 137,603 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-07 | Grant/award (50,000 shares) |
| 2026-08-07 | Disposition to the issuer (137,603 shares) |
| 2026-08-07 | Grant/award (137,603 shares) |
Keywords
insider transaction, Form 4, OKUR, OnKure Therapeutics, Inc., neutral, Dylan Hartley
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.